A Review: Highlighting the Links between Epigenetics, COVID-19 Infection, and Vitamin D

Int J Mol Sci. 2022 Oct 14;23(20):12292. doi: 10.3390/ijms232012292.

Abstract

The highly transmittable and infectious COVID-19 remains a major threat worldwide, with the elderly and comorbid individuals being the most vulnerable. While vaccines are currently available, therapeutic drugs will help ease the viral outbreak and prevent serious health outcomes. Epigenetic modifications regulate gene expression through changes in chromatin structure and have been linked to viral pathophysiology. Since epigenetic modifications contribute to the life cycle of the virus and host immune responses to infection, epigenetic drugs are promising treatment targets to ameliorate COVID-19. Deficiency of the multifunctional secosteroid hormone vitamin D is a global health threat. Vitamin D and its receptor function to regulate genes involved in immunity, apoptosis, proliferation, differentiation, and inflammation. Amassed evidence also indicates the biological relations of vitamin D with reduced disease risk, while its receptor can be modulated by epigenetic mechanisms. The immunomodulatory effects of vitamin D suggest a role for vitamin D as a COVID-19 therapeutic agent. Therefore, this review highlights the epigenetic effects on COVID-19 and vitamin D while also proposing a role for vitamin D in COVID-19 infections.

Keywords: COVID-19; SARS-CoV-2; epigenetics; vitamin D.

Publication types

  • Review

MeSH terms

  • Aged
  • COVID-19*
  • Chromatin
  • Epigenesis, Genetic
  • Hormones
  • Humans
  • SARS-CoV-2
  • Vitamin D / metabolism
  • Vitamin D / pharmacology
  • Vitamin D / therapeutic use
  • Vitamin D Deficiency* / complications
  • Vitamin D Deficiency* / drug therapy
  • Vitamin D Deficiency* / genetics
  • Vitamins / pharmacology
  • Vitamins / therapeutic use

Substances

  • Vitamin D
  • Vitamins
  • Hormones
  • Chromatin